Trade Alert: A Boxing Day Triple
One trade from our system's current top ten names, one from our Multibaggers list, plus a special situation: a biotech buyout lotto ticket.
Unboxing Three Trades For Today
We’ve got three trades today: one from Portfolio Armor’s Top Names from Wednesday night, and one from our Multibaggers list, and a special situation from our Market Watchers list.
Today’s Top Name
The first name is an engineering and construction company that builds power plants and other large energy infrastructure projects—exactly the kind of reindustrialization / AI-adjacent “picks and shovels” play we’ve been focusing on as data centers and onshoring drive demand for new capacity. The last time it appeared in our top names list back in September, we structured an options trade on it and turned a debit of $0.45 per contract into $7.70 when we exited. It’s pulled back from its recent high, the current setup and RSI look constructive, and it just resurfaced near the top of our rankings—so I’m taking another swing at it with a similar defined-risk structure below.
Today’s Multibagger Name
The second name is a large-cap animal-health company that came to my attention via my Multibaggers list. For newer readers, the Multibaggers list is a curated set of X accounts run by analysts and traders with documented histories of identifying stocks that have gone on to deliver 100%+ gains over the last year. On Chartmill, this one scores 9 for profitability, 7 for financial health, 6 for valuation, and 5 for growth, and its chart shows a reasonable base rather than a breakdown. Just as important, the February options combo I’m using on it is currently priced below Black-Scholes fair value, giving us a defined-risk way to participate if sentiment improves after its next earnings report.
Today’s Special Situation
I’m also adding a small special situation trade tied to a tiny biotech that licensed its blood–brain barrier gene-therapy capsid technology to a much larger pharma partner. That partner is highlighting the collaboration in its presentation at this year’s J.P. Morgan healthcare conference, and there are two more potential catalysts after that: the biotech’s March earnings report and a capsid-focused case study scheduled for an April conference in Dubai. I’m treating this as a defined-risk lotto—using a small, leveraged options position sized below my usual risk per trade—where we either benefit from an upside surprise or buyout over the next few months, or lose a clearly limited amount if nothing comes of the speculation.
Full details on all three trades are below, including preset exit instructions, as usual, so we don’t have to babysit anything.
Today’s Top Names Trade
(Reindustrialization / Power infrastructure theme)
